Chemoprophylaxis for Pneumocystis carinii pneumonia (PCP) is routinely given after allogeneic blood or marrow transplantation. We evaluated the effectiveness of dapsone prophylaxis (50 mg orally twice daily, 3 times per week) compared with twice-weekly trimethoprim-sulfamethoxazole (TMP-SMZ) in preventing PCP after allogeneic blood or marrow transplantation. Patients included all ( ) who received allogeneic blood or marrow transn = 646 plants between 1 September 1993 and 31 December 1996 who survived at least 100 days after transplantation. A cohort of 111 dapsone recipients was compared with the remaining 535 who received TMP-SMZ. Ten patients developed PCP; 8 were taking dapsone. PCP incidence in the TMP-SMZ cohort was 0.37% versus 7.2% for dapsone. The relative risk for PCP associated with dapsone use was 18.8 ( ) and was not accounted for by age, clinical P ! .001 extensive chronic graft-versus-host disease, donor source, or malignant relapse. Dapsone prophylaxis at this dosage is associated with significantly higher rates of PCP than is TMP-SMZ after allogeneic marrow transplantation. We advise caution in prescribing alternatives to TMP-SMZ prophylaxis in this setting.
Pneumocystis carinii pneumonia (PCP) contributes to the morbidity and mortality of patients with HIV infection, acute lymphocytic leukemia, and other defects of cell-mediated immunity. Up to 16% of marrow transplant recipients develop PCP if chemoprophylaxis is not provided [1] . Before the routine use of twice-weekly trimethoprim-sulfamethoxazole (TMP-SMZ) as prophylaxis, the rate of development of PCP at our institution was 6.8%, and all of these cases occurred between 40 and 80 days after transplantation [2] . Prophylaxis with TMP-SMZ was associated with a decrease in the incidence of PCP within 6 months of marrow transplantation to 0.15% [2] . Mortality rates have varied, and rates as high as 89% have been reported [3] .
Currently, most cases of PCP occur 16 months after blood or marrow transplantation; the incidence of PCP varies 0.45%-13% [4, 5] . In a recent review, Sepkowitz et al. [4] reported rates between 0.45% and 2.6% for PCP occurring any time after transplantation. The number of patients at risk for late PCP was not defined in this study, but of the 23 reported cases, 9 occurred after 6 months. Lyytikainen et al. [5] reported a rate of late PCP of 13%, but none of these patients was receiving prophylaxis at the time of diagnosis. Risk factors for PCP occurring 16 months after transplantation include ongoing corticosteroid use, malignant relapse, and extensive chronic graft versus host disease (GVHD) [3] .
Many blood and marrow transplantation centers use PCP chemoprophylaxis for at least 6 months after transplantation. Investigators advise continued prophylaxis for patients with ongoing corticosteroid use, malignant relapse, or clinical extensive GVHD [2, 3, [6] [7] [8] . The most commonly used and effective prophylactic drug combination is TMP-SMZ. However, adverse drug reactions (usually allergy to sulfa drugs, gastrointestinal intolerance, or marrow suppression) may prompt discontinuation of the drug. As many as 47% of HIV-infected patients require an alternative to TMP-SMZ because of side effects [9] . The true rate of adverse reactions to TMP-SMZ in the marrow transplant population is unknown but probably in the range of 5%-15% (M. Boeckh, unpublished data).
Alternatives to TMP-SMZ prophylaxis include aerosolized or intravenous pentamidine [2, 10] and dapsone. In a small prospective study, Link et al. [10] found no cases of PCP among 43 marrow recipients treated with monthly aerosolized pentamidine for 6 months. However, more than half of the patients were followed for !9 months. In contrast, a retrospective review by Walter et al. [2] noted PCP rates of 7.8% in patients treated with twice-monthly intravenous pentamidine.
Prophylaxis with dapsone among HIV-infected patients has been used with variable success as an alternative to TMP-SMZ [9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Its use in this setting has recently been reviewed [20] . In addition, dapsone prophylaxis has been used successfully for pediatric marrow transplant patients [21] . On the basis of these experiences, prophylaxis with dapsone has been advocated [7, 8] and has been used routinely as second-line prophylaxis at our center among marrow transplant recipients who are intolerant of TMP-SMZ. The purpose of this study is to evaluate the efficacy of intermittent dapsone compared with standard TMP-SMZ prophylaxis in preventing PCP after allogeneic blood or marrow transplantation.
Methods
Study population. We used a retrospective cohort design. The study included all patients at the Fred Hutchinson Cancer Research Center (FHCRC) who received of allogeneic blood and marrow transplants between 1 September 1993 and 31 December 1996 who survived at least 100 days after transplantation. The dapsone cohort was composed of patients who had received at least 1 dose of dapsone for PCP prophylaxis. The TMP-SMZ cohort was all other patients who received transplants during the same period. The outcome of interest was PCP. Patient characteristics were identified from prospectively collected data and pharmacy records.
PCP prophylaxis regimens. At FHCRC, PCP prophylaxis is administered according to standardized clinical practice guidelines. Standard prophylaxis is TMP-SMZ, given as one double-strength tablet (800 mg sulfamethoxazole, 160 mg trimethoprim) twice daily orally for 7-14 days before transplantation. TMP-SMZ is discontinued 2 days before transplantation and resumed after transplantation when the absolute neutrophil count exceeds 500/mm 3 for at least 2 consecutive days, or by day 30. TMP-SMZ (one doublestrength tablet twice daily on 2 days per week) is then continued for at least 6 months, or for as long as patients have evidence of clinical extensive chronic GVHD or continue to receive immunosuppressive therapy. The guideline recommends that patients who are allergic to TMP-SMZ undergo desensitization. If desensitization cannot be performed before transplantation, then the process is started after transplantation when an absolute neutrophil count is 1500 for 3 days, or by day 30. Desensitization is done by a modified method [22] that uses a stock solution of TMP at 40 mg/5 mL and SMZ at 200 mg/5 mL. The stock solution is diluted at 1 mL of stock in 9 mL of saline for the first 5 days of the desensitization. On days 1-5, the patient receives the dilute solution in doses of 0.25 mL, 0.5 mL, 1 mL, 2 mL, and 4 mL, respectively. On days 6-9 the patient receives full-strength stock solution in doses of 0.5 mL, 1 mL, 2 mL, and 4 mL, respectively. On day 10, 1 single-strength tablet (400 mg of SMZ) is given to adults and one-half single-strength tablet to children !12 years old. If this is tolerated, dosing is continued as 1 single-strength tablet b.i. Prophylaxis with dapsone is recommended only for patients for whom desensitization fails or who are otherwise intolerant of TMP-SMZ and do not have glucose-6-phosphate dehydrogenase deficiency. Pretransplantation dapsone is given in doses of 50 mg orally b.i.d. for 7-10 days and is discontinued 2 days before transplantation. After transplantation, dapsone is given in doses of 50 mg orally b.i.d. 3 times per week for at least 6 months or for as long as patients have evidence of clinical extensive chronic GVHD or continue to receive immunosuppressive therapy. Most patients initially receive TMP-SMZ. A subset of these patients require conversion to dapsone.
Diagnosis of PCP. Cases of PCP were identified from prospectively collected data in the long-term follow-up department at FHCRC. Diagnosis was confirmed by histological demonstration of P. carinii organisms with methenamine silver-stained specimens of bronchoalveolar lavage fluid, transbronchial biopsy specimens, or open lung biopsy tissue. Suspected cases without cytological or histological confirmation were considered not to represent PCP.
Statistical analysis. Baseline categorical data for the 2 cohorts were compared by means of the x 2 test. The incidence of PCP was estimated both as a simple proportion and per 100 person-years of follow-up. The hazards of PCP were compared by use of the Cox proportional hazards regression method. Variables potentially associated with PCP that were analyzed included chemoprophylaxis regimen, the presence of clinical extensive chronic GVHD, age at transplantation, relapse of malignancy, and use of total body irradiation in the conditioning regimen. Chronic clinical extensive GVHD and relapse of malignancy were treated as time-dependent covariables in the regression models. P values associated with the regression models are derived from the Wald test and are twosided.
Results
Six hundred forty-six patients received allogeneic blood or marrow transplants between 1 September 1993 and 31 December 1996 and survived at least 100 days after transplantation. The dapsone cohort contained 111 patients who had received at least 1 dose of dapsone before or after transplantation. The remaining 535 patients made up the standard cohort. Characteristics of the 2 cohorts are shown in table 1. A statistically larger proportion of patients who received dapsone were aged 121 years, had chronic myelogenous leukemia, and had clinical extensive chronic GVHD (table 1) .
Ten cases of confirmed PCP were identified among the study subjects. These pneumonias occurred 163-467 days after transplantation (median, 306 days). Seven other cases of PCP that occurred during this period were excluded, either because they were in persons who received transplants before the study dates or because they occurred in recipients of autologous grafts. Three additional patients with pneumonia but no cytological confirmation of PCP were considered not to have PCP. All 10 cases of PCP included in the study had histological confirmation of the diagnosis by bronchoalveolar lavage, transbronchial biopsy, or open lung biopsy (table 2) .
Ages of the patients with PCP ranged from 25 to 48 years (mean, 37 years). Patients with PCP included 8 men and 2 women. All patients with PCP had undergone transplantation for treatment of malignancies: chronic myelogenous leukemia (4), acute myelogenous leukemia (2), non-Hodgkin's lymphoma (2), myelodysplastic syndrome (1), and chronic lymphocytic leukemia (1). Donor sources included human leukocyte antigen (HLA)-matched siblings (4), HLA-mismatched siblings (2), and matched unrelated donors (4). Eight of the 10 patients with PCP had acute GVHD after transplantation. Of those 8, 7 developed extensive chronic GVHD. An additional patient who had not had acute GVHD developed extensive chronic GVHD. One patient was in malignant relapse at the time of diagnosis of PCP. Seven of the 10 patients died within 4 weeks of the diagnosis of PCP. The remaining 3 recovered and were discharged from the hospital.
Of the 10 patients who developed PCP, 8 were in the dapsone cohort. Dapsone was ordered in doses of 50 mg orally b.i.d., thrice weekly, for all 8 patients. One patient was possibly noncompliant; another appears to have had the order for dapsone inadvertently overlooked for a 2-month period but was taking dapsone at diagnosis. The duration of dapsone use ranged between 37 and 574 days (mean, 263 days; median, 212 days).
The remaining 2 patients were in the TMP-SMZ cohort. Neither was taking TMP-SMZ at the time of diagnosis.
During the study period, PCP was observed in 0.37% of patients in the TMP-SMZ cohort (0.28 cases per 100 personyears) versus 7.2% of the patients in the dapsone group (4.84 cases per 100 person-years; table 3). The relative risk for developing PCP in the dapsone cohort was 18.8 (95% CI, 4.0-88.6;
). Other variables potentially related to the develop-P ! .001 ment of PCP (age at transplantation, presence of clinical extensive chronic GVHD, malignant relapse, and total body irradiation) were each added to the regression model containing dapsone alone. Although the number of events (cases of PCP) precludes fitting a model with all variables considered simultaneously, the inclusion of each individual variable did not have an effect on the qualitative strength of the association of dapsone with PCP.
Discussion
We found that PCP chemoprophylaxis with dapsone was associated with a statistically higher incidence of PCP than was prophylaxis with TMP-SMZ. There were 8 cases of PCP in the dapsone cohort, representing an incidence of 4.84 per 100 person-years, versus 2 cases in the standard group, an incidence of 0.28 cases per 100 person-years. The relative risk for PCP in the dapsone cohort was 18.8. The duration of follow-up within each of the cohorts ranged from as short as 6 months to 13 years, but the average follow-up between the groups was similar (1.49 years in the dapsone cohort vs. 1.36 years in the TMP-SMZ cohort). The incidence of PCP in the TMP-SMZ cohort was similar to that previously observed, whereas the incidence in the dapsone cohort was similar to the rate seen historically in the absence of any prophylaxis [2] (figure 1). These findings suggest that dapsone, in the doses used in this It is unclear why dapsone would be ineffective in this setting. One possible explanation is that the dosing schedule used at our center was inadequate. Studies of small numbers of patients show comparable results between twice-weekly dosing of dapsone and aerosolized pentamidine [13, 23] . However, studies comparing dapsone with TMP-SMZ suggest that only daily dosing of dapsone provides protection similar to that provided by TMP-SMZ [9, [15] [16] [17] [18] [19] [20] . Second, although dapsone is nearly 100% bioavailable in normal patients [24] , our patients may have had gastrointestinal malabsorption related to chronic GVHD. Such a phenomenon of decreased drug absorption has been described with cyclosporine administration in patients with chronic GVHD [25] . Also, genetic polymorphism of the hepatic N-acetylation pathway may produce highly variable interindividual dapsone blood and tissue levels [26, 27] . The reduced efficacy in preventing PCP associated with low intermittent doses of dapsone used in this study may be due to differences in dosing and metabolism. However, dividing the total daily dose of dapsone in a similar fashion did not seem to affect the successful prophylaxis of PCP in a large, randomized trial among HIV-infected patients [9] .
Recently, dapsone prophylaxis has been used successfully for pediatric bone marrow transplant patients [21] . In a retrospective analysis, Maltezou et al. [21] found no cases of confirmed PCP among 35 pediatric bone marrow transplant recipients (25 allogeneic and 8 autologous) who were treated with dapsone (50 mg/m 2 /week). This study included younger patients and recipients of autologous grafts. In addition, the patients had a lower incidence of clinical extensive chronic GVHD (36% vs. 67% in our study). Moreover, the average duration of followup in their study was 208 days versus 543 for the dapsone group in the current study. These are significant differences, since most cases of PCP after bone marrow transplantation happen late and occur in allogeneic recipients with chronic GVHD who are receiving steroids.
Our study has several limitations. First, other factors that have been previously suggested as being associated with PCP could be responsible for the apparent association observed between dapsone and PCP. Cox regression models that adjusted for such variables, however, did not qualitatively change our conclusions. Nonetheless, the amount of information that such models can provide is severely limited by the small number of PCP cases. Last, it is possible that factors associated with TMP-SMZ intolerance (and, therefore, subsequent dapsone administration) might be associated with the development of PCP. Such an association would not diminish the validity of an increased rate of PCP among the dapsone cohort.
In conclusion, caution should be exercised in prescribing dapsone at this dosage for PCP prophylaxis after allogeneic blood or marrow transplantation. The reasons for dapsone's lack of efficacy are unclear. The documented efficacy of TMP-SMZ prophylaxis warrants its use whenever possible. Desensitization to sulfamethoxazole should be attempted in patients with allergic reactions before opting for any other chemoprophylaxis. In nonallergic patients, rechallenge with TMP-SMZ should always be attempted after the adverse reaction has improved. Options for transplant recipients who cannot tolerate TMP-SMZ should include dapsone in once-daily doses [9] or aerosolized pentamidine. Lower doses of TMP-SMZ may also be effective as prophylaxis. Finally, agents with favorable toxicity profiles, such as atovaquone [28, 29] , may prove useful in the future. However, the requirement that atovaquone be admin-istered with a high-fat meal, and the drug's gastrointestinal side effects [29] (which are often the reason for alternative prophylaxis in the first place), may constitute problems for high-risk allogeneic transplant recipients.
This study illustrates the need for continued vigilance for PCP among allogeneic blood or marrow recipients who receive chemoprophylaxis other than TMP-SMZ. In addition, there is a need for continued data acquisition regarding the relative efficacy and toxicity of all alternative PCP prophylactic regimens in these populations.
